Navigation Links
Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
Date:1/9/2012

ROCKVILLE, Md., Jan. 9, 2012 /PRNewswire/ -- BioReliance, a leading provider of global biopharmaceutical testing services, announced today that it has agreed to be acquired by Sigma-Aldrich Corporation (NASDAQ: SIAL).  Avista Capital Partners, the majority owner of BioReliance Holdings, Inc., agreed to sell the company for $350 million in cash.  The acquisition is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012.

BioReliance provides critical services that include biologics testing, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science clients worldwide.  BioReliance's service offering helps facilitate drug development, manufacturing and commercialization activities.  The Company's ability to develop and execute global testing protocols in compliance with various regulatory standards enables BioReliance's clients to register products with regulatory agencies worldwide.

Sigma-Aldrich is a leading Life Science and High Technology company.  Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing.

Commenting on the transaction, BioReliance's President and CEO Charles Harwood stated, "The acquisition of BioReliance by Sigma-Aldrich creates one of the broadest product and service offerings for the development and manufacture of biological drugs.  In addition, BioReliance's Specialized Toxicology and Animal Health Services segments are complementary to other Sigma-Aldrich product and technology areas."

Avista Capital Partners acquired BioReliance in 2007.  With regards to the acquisition of BioReliance by Sigma-Aldrich, Avista Partner and President David Burgstahler commented
'/>"/>

SOURCE BioReliance Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
2. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
3. Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
4. Private Equity and Venture Capital (PE/VC) Activity in Medical Devices - Number of Investments in Smaller Companies has Increased over the Past Four Years
5. IsZo Capital Writes to Taro Pharmaceutical Board Commenting on Management Proposals for 2011 Annual Shareholder Meeting; Reflecting on Sun Pharmas Response to Similar 2009 Proposals
6. IzSo Capital Writes to Taro Pharmaceutical Board Demanding that Liability Protection Management Proposals be Removed Immediately from Agenda for Annual Shareholders Meeting
7. Physicians Capital Investments Announces Relocation of its Corporate Headquarters to Dallas, TX
8. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
9. WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering
10. WestPark Capital Announces $2.6 Million IsoRay Offering
11. Physicians Capital Investments Announces Pedro Vergne-Marini, MD Named to Beckers ASC Review "350 People in the ASC Industry to Know"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass. , July 29, 2014  Instrumentation Laboratory (IL) ... including a new corporate logo. This is part of a ... Founded in Boston, MA , ... family of companies since 1992.  Other companies in the group ... Biokit and Systelab ( Barcelona, Spain ).  Like ...
(Date:7/29/2014)... LINCOLNSHIRE, Ill. , July 29, 2014  Sysmex ... equipment and information systems technology, will feature an exhibit ... (AACC) Annual Meeting and Clinical Lab Expo in ... 31, 2014. "We are extremely excited ... tremendous opportunity to interact with our customers and continue ...
(Date:7/29/2014)... LAKE CITY , July 29, 2014  The ... The Grand American Hotel in Salt Lake ... speakers representing some of most respected healthcare organizations in ... Health Catalyst , is an industry conference devoted to ... healthcare analytics,  an essential element of both accountable care ...
Breaking Medicine Technology:Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 2New Product Offerings Highlight Sysmex's Presence at 2014 AACC in Chicago 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 The ... Gossip reveals the inside story to Gary M. Levin’s ... a remarkable cure method for this serious disorder. Levin ... most discouraging conditions that can be found in patients. ... MD and surgeon. For many years, Levin has worked ...
(Date:7/29/2014)... Winter is here down under, and ... Sydney’s central business district. That is, until a troop ... the otherwise ordinary day into a celebration—a celebration of ... advocates of The Truth About Drugs, a drug prevention ... They woke up the city with a rousing performance ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Daily Gossip reveals ... 5 step holistic system that will permanently eliminate all the ... Coleman his natural treatment will banish symptoms such as mild ... beeping sound heard by patients will be gone forever. , ... 60 days. The author of this program says that at ...
(Date:7/29/2014)... TUESDAY, July 29, 2014 (HealthDay News) --,The time at ... affect their chances for survival, new research suggests. ... weekends or during holidays is associated with a 13 ... business hours, researchers report. Every year, more than ... most severe type of heart attack, which is caused ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... Aeras and the China National Biotech Group (CNBG) today ... organizations to pursue opportunities to jointly develop tuberculosis (TB) vaccines ... The partnership is intended to leverage both organizations, capabilities ... a major public health priority in China, where there are ...
... Serena Gordon HealthDay Reporter , MONDAY, July 25 (HealthDay ... worry to add to their list: Kids younger than 10 years ... on their own. New research found that while children ... the street solo -- they do stop and look both ways ...
... specific genes shuts down the mass production of antibodies launched ... by scientists at The University of Texas MD Anderson Cancer ... "Regulatory T cells prevent unwanted or exaggerated immune system ... been unclear," said paper senior author Chen Dong, Ph.D., professor ...
... ALBUQUERQUE, N.M. Americans are used to drinking from ... water utilities might be vulnerable to terrorist attacks or ... an open-source software developed by Sandia National Laboratories ... public water systems can be protected through enhanced detection ...
... , MONDAY, July 25 (HealthDay News) -- As ... school this fall, the American Lung Association urged parents to ... and help ease their transition back to the classroom. ... back-to-school necessities, it is even more essential for parents of ...
... of oncologists in the Program in Women,s Oncology at Women ... guide to the human papilloma virus (HPV) so physicians can ... women with the virus. Dx/Rx: Human Papilloma Virus was ... oncology at Women & Infants and associate professor of obstetrics ...
Cached Medicine News:Health News:Aeras and China National Biotech Group sign memorandum of understanding for TB vaccine R&D 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:Specialized regulatory T cell stifles antibody production centers 2Health News:Specialized regulatory T cell stifles antibody production centers 3Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 2Health News:Sandia's CANARY software protects water utilities from terrorist attacks and contaminants 3Health News:Preparation Key When Kids With Asthma Go Back to School 2Health News:Oncologists publish HPV manual for physicians 2
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... quadripolar pacing wire design offers ... sensing in the atrium and ... wires in one lead design. ... and ventricle are color-coded for ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: